Cosmo Pharmaceuticals (OTC:CMOPF) Trading 9.1% Higher – What’s Next?

Shares of Cosmo Pharmaceuticals (OTC:CMOPF) rose 9.1% on Wednesday . The stock traded as high as C$73.00 and last traded at C$73.00. Approximately 1,170 shares traded hands during mid-day trading, an increase of 352% from the average daily volume of 259 shares. The stock had previously closed at C$66.93.

Cosmo Pharmaceuticals Stock Down 1.4 %

The stock’s 50 day moving average is C$70.43 and its two-hundred day moving average is C$82.98.

Cosmo Pharmaceuticals Company Profile

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy.